IGF-1 LR3 Cycle: Dosage, Protocol & What to Expect

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1. The "LR3" modification refers to an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These changes reduce binding to IGF-binding proteins (IGFBPs), resulting in:

• Extended half-life: Approximately 20–30 hours compared to 12–15 hours for standard IGF-1.
• Greater bioavailability: More free IGF-1 available to interact with receptors.
• Enhanced potency: Roughly 2–3x more potent than native IGF-1 in cell culture studies.

IGF-1 LR3 acts primarily through the IGF-1 receptor (IGF-1R) to promote protein synthesis, nitrogen retention, and hyperplasia (the formation of new muscle cells) — a mechanism distinct from the hypertrophy (cell enlargement) driven by most anabolic compounds.

The following protocols are commonly discussed in research and community literature. These are not medical recommendations:

• Dosage range: 20–50 mcg per day for most users. Advanced researchers may use up to 80–100 mcg, though higher doses increase the risk of side effects.
• Injection timing: Typically administered post-workout or split into bilateral site injections into target muscle groups.
• Injection route: Intramuscular (IM) or subcutaneous (SubQ). IM injections into trained muscles are preferred for localized effects.
• Cycle length: 4–6 weeks on, followed by 4–6 weeks off. Extended use beyond 6 weeks is generally discouraged due to receptor desensitization.
• Reconstitution: IGF-1 LR3 is typically reconstituted with bacteriostatic water or acetic acid solution and stored refrigerated.

IGF-1 LR3 can be used standalone or as part of a broader research protocol. Common considerations include:

• Post-workout window: Many protocols call for injection within 30 minutes of training to capitalize on increased blood flow and nutrient delivery to muscles.
• Bilateral injections: Splitting the daily dose between two muscle groups (e.g., 25 mcg per side) is a common approach for symmetrical development.
• Stacking with GH: Some researchers combine IGF-1 LR3 with growth hormone secretagogues like ipamorelin. The rationale is that exogenous IGF-1 supplements the GH-IGF axis from the downstream side.
• Avoid insulin overlap: Due to IGF-1 LR3's insulin-like effects, caution is warranted regarding blood sugar management. Do not combine with insulin without medical supervision.

Potential side effects associated with IGF-1 LR3 use include:

• Hypoglycemia: IGF-1 LR3 can lower blood sugar. Have fast-acting carbohydrates available during use.
• Gut growth: Prolonged high-dose use has been associated with visceral organ growth in anecdotal reports.
• Joint pain: Some users report transient joint discomfort, particularly at higher doses.
• Injection site reactions: Redness, swelling, or soreness at the injection site.
• Theoretical cancer risk: IGF-1 promotes cell proliferation. Individuals with a history of cancer or pre-cancerous conditions should avoid IGF-1 LR3.

Risk mitigation: Start at the lowest effective dose, limit cycles to 4 weeks initially, monitor blood glucose, and take adequate time off between cycles.

Peptide purity is critical with IGF-1 LR3 due to its potency. Look for suppliers that provide:

• Third-party HPLC purity testing (≥98%)
• Mass spectrometry verification
• Proper lyophilization and cold storage
• Transparent batch-specific COAs

Ascension Peptides is a recommended source for research-grade IGF-1 LR3, offering full third-party testing documentation and consistent quality across batches.